NASDAQ: NVCN
TSX VENTURE: NVC
VANCOUVER, June 12, 2014 /PRNewswire/ - Neovasc Inc.
("Neovasc" or the "Company") (NASDAQ: NVCN) (TSXV: NVC) is pleased
to announce that it has been listed in the 2014 PROFIT 500 as one
of Canada's fastest growing
companies. Having achieved an average revenue growth of
approximately 50% year over year since its inception in 2008,
Neovasc attributes its success to its strong customer
relationships, attention to operational excellence, and dedication
to furthering advances in cardiovascular device technology.
"We appreciate this recognition of our success and share the
honour with each of our employees, customers, shareholders, and
industry partners and offer our congratulations to all those named
in this year's PROFIT 500," states Alexei
Marko, CEO at Neovasc.
In addition to recently announcing strong clinical trial results
for its Reducer™ product for the treatment of refractory angina,
the Company's Tiara™ valve is now widely recognized as a leading
program for transcatheter mitral valve replacement. Neovasc's
tissue development, supply and manufacturing business provides
services to a range of customers around the world as a trusted
provider of biological tissue and cardiovascular device contract
manufacturing services.
Published annually, the PROFIT 500 lists and profiles
Canada's Fastest-Growing
Companies by five-year revenue growth and gives entrepreneurs and
their businesses the recognition they deserve for their
achievements and contributions to Canada.
About PROFIT and PROFITguide.com
PROFIT: Your Guide to Business Success is Canada's preeminent media brand dedicated to
the management issues and opportunities facing small and mid-sized
businesses. For 32 years, Canadian entrepreneurs across a vast
array of economic sectors have remained loyal to PROFIT because
it's a timely and reliable source of actionable information that
helps them achieve business success and get the recognition they
deserve for generating positive economic and social change. Visit
PROFIT online at PROFITguide.com.
About Canadian Business
Founded in 1928, Canadian Business is the longest-serving,
best-selling and most-trusted business publication in the country.
With a readership of more than 800,000, it is the country's premier
media brand for executives and senior business leaders. It fuels
the success of Canada's business
elite with a focus on the things that matter most: leadership,
innovation, business strategy and management tactics. We provide
concrete examples of business achievement, thought-provoking
analysis and compelling storytelling, all in an elegant package
with bold graphics and great photography. Canadian Business—what
leadership looks like.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Tiara™
technology in development for the transcatheter treatment of mitral
valve disease, the Neovasc Reducer™ for the treatment of refractory
angina and a line of advanced biological tissue products that are
used as key components in third-party medical products including
transcatheter heart valves. For more information, visit:
www.neovasc.com.
Statements contained herein that are not based on historical
or current fact, including without limitation statements containing
the words "anticipates," "believes," "may," "continues,"
"estimates," "expects," and "will" and words of similar import,
constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian
securities laws. Such forward looking statements involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, events or developments to be materially different
from any future results, events or developments expressed or
implied by such forward-looking statements. Such factors include,
among others, the following: general economic and business
conditions, both nationally and in the regions in which the Company
operates; the merits and the Company's defence of the lawsuit filed
by CardiAQ, listing of the Company's securities on the TSX, our
anticipated use of proceeds from any financings, a history of
losses and lack of and uncertainty of revenues, ability to obtain
required financing, receipt of regulatory approval of product
candidates, ability to properly integrate newly acquired
businesses, technology changes; competition; changes in business
strategy or development plans; the ability to attract and retain
qualified personnel; existing governmental regulations and changes
in, or the failure to comply with, governmental regulations;
liability and other claims asserted against the Company; and other
factors referenced in the Company's filings with Canadian
securities regulators. Although the Company believes that
expectations conveyed by the forward-looking statements are
reasonable based on the information available to it on the date
such statements were made, no assurances can be given as to the
future results, approvals or achievements. Given these
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements except as
otherwise required by applicable law.
SOURCE Neovasc Inc.
